Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Genmab
Emory University
Children's Oncology Group
Medical University of Vienna
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
Regeneron Pharmaceuticals
St. Jude Children's Research Hospital
Columbia University
Children's Oncology Group
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
City of Hope Medical Center
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC
Medical College of Wisconsin
Weill Medical College of Cornell University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
University of Miami
The University of Texas Health Science Center, Houston
Alliance for Clinical Trials in Oncology
Universitätsklinikum Hamburg-Eppendorf
Washington University School of Medicine
Milton S. Hershey Medical Center
National Institutes of Health Clinical Center (CC)
Arog Pharmaceuticals, Inc.
Queen Mary University of London
Masonic Cancer Center, University of Minnesota
University of Nebraska
University of Nebraska
Arog Pharmaceuticals, Inc.
European Organisation for Research and Treatment of Cancer - EORTC
University of Nebraska
University of Nebraska
Children's Oncology Group
OHSU Knight Cancer Institute
Shandong University
Children's Hospital Los Angeles
Dana-Farber Cancer Institute
Weill Medical College of Cornell University
Goethe University
Medstar Health Research Institute
OHSU Knight Cancer Institute
Children's Oncology Group